Risk Profile Improvements

  • Goodwill Impairment (removed) — Goodwill impairment charge of $3.7M recorded in 2024 is absent from 2025 results.
NASDAQ: ZNTL Zentalis Pharmaceuticals, Inc. 10-K

Zentalis completes 40% workforce cut, narrows focus to azenosertib; cash runway to late 2027

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 26, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ZNTL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 4, 2026 3:27 AM